Plant · Scientific monograph
Harpagophytum procumbens
Devil's claw
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Musculoskeletal research, Traditional herbal use
Research overview
Historical use
Devil's claw secondary root is used in traditional herbal preparations; EMA assessment distinguishes root preparations and does not find a sufficient basis for well-established efficacy [3].
Modern research context
A systematic review of 12 trials found that the evidence varied by preparation and harpagoside content, with heterogeneity limiting pooling [1]. A 60-person trial compared a named product with meloxicam over unequal treatment periods; it found no significant superiority between groups [2]. These findings are product- and indication-specific.
Adverse effects
Adverse-event evidence varies by formulation and trial; available sources do not establish long-term safety across powders and extracts [1-3].
Contraindications
EMA does not establish well-established use. Avoid generalizing findings among powdered root, aqueous extract and ethanolic extracts [1-3].
Clinical and phytochemical data
Used part
Secondary roots/tubers; human trials used specific powder or extract preparations and are not interchangeable [1-3].
Primary active compounds
Harpagoside is used to characterize some preparations; amount varies by product [1,3].
Mechanism of action
Clinical studies do not establish a single validated human mechanism for the diverse preparations [1,2].
Pharmacokinetics
Absorption
No general human PK profile identified across the distinct devil's-claw preparations [1-3].
Distribution
Not characterized.
Metabolism
Not characterized.
Excretion
Not characterized.
Safety and interactions
Drug interactions
No comprehensive clinical interaction profile established by the cited sources.
Toxicity
Safety evidence is formulation-specific; trial heterogeneity and short follow-up limit conclusions [1,2].
Special precautions
Pregnancy
Medicinal-use safety in pregnancy is not established by the cited trials.
Lactation
Lactation safety is not established.
Hepatic impairment
No impairment-specific evidence identified; product labeling and clinician review are appropriate where underlying disease is present.
Renal impairment
No impairment-specific evidence identified.
Sources and references
- [1] Joel J. Gagnier, Sigrun Chrubasik, Eric Manheimer. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complementary and Alternative Medicine. 2004;4:13. PMID: 15369596. DOI: 10.1186/1472-6882-4-13.
- [2] Hamid Reza Farpour et al. The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial. Evidence-Based Complementary and Alternative Medicine. 2021;2021:5596892. PMID: 34712343. DOI: 10.1155/2021/5596892.
- [3] EMA/HMPC. Assessment report on Harpagophytum procumbens and/or H. zeyheri, radix.